Lowell Shinn
Hematology & Oncology · Belpre, OHNPI 1811961451
Payments from drug & device makers
Across 98 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$378
- Pfizer$310
- E.r. Squibb & Sons, L.L.C.$224
- Astellas Pharma US Inc$116
- Bristol Myers Squibb$94
- Gilead$69
- plus $609 from 19 others
What the payments were for
- Food & beverage$1,66793%
- Education$1337%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 22 | $378 |
| Pfizer | 17 | $310 |
| E.r. Squibb & Sons, L.L.C. | 14 | $224 |
| Astellas Pharma US Inc | 2 | $116 |
| Bristol Myers Squibb | 5 | $94 |
| Gilead(2 entities) | 4 | $69 |
| AVEO Pharmaceuticals, Inc. | 3 | $61 |
| Merck | 3 | $59 |
| AstraZeneca | 3 | $55 |
| Sumitomo Pharma America, Inc. | 3 | $48 |
| Bayer | 3 | $46 |
| AbbVie | 2 | $43 |
| Incyte Corporation | 2 | $38 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Array Biopharma Inc | 2 | $33 |
| Acrotech Biopharma Inc. | 2 | $29 |
| Progenics Pharmaceuticals, Inc. | 1 | $25 |
| Mirati Therapeutics, Inc. | 1 | $24 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $18 |
| Servier Pharmaceuticals LLC | 1 | $18 |
| Nuvation Bio Inc. | 1 | $17 |
| Sanofi | 1 | $17 |
| GSK | 1 | $16 |
| EMD Serono, Inc. | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $14 |
How this compares
$1,800 in reported general payments places this provider in the 35th percentile of 450 hematology & oncology providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 23 | $388,439 |
| CalquenceAcalabrutinib Maleate | 18 | $266,898 |
| DopteletAvatrombopag Maleate | 18 | $235,531 |
| RevlimidLenalidomide | 13 | $232,677 |
| Lenalidomide | 13 | $149,838 |
| Imatinib Mesylate | 27 | $61,719 |
| EliquisApixaban | 49 | $49,925 |
| XareltoRivaroxaban | 29 | $21,006 |
| Anagrelide Hcl | 13 | $1,620 |
| Ondansetron Hcl | 80 | $1,508 |
| Oxycodone Hcl | 46 | $1,184 |
| Hydroxyurea | 37 | $1,082 |
| Anastrozole | 53 | $1,052 |
| Pregabalin | 26 | $1,050 |
| Bicalutamide | 68 | $987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $18 | $388,43923 claims |
| AstraZenecaCalquence | $55 | $266,89818 claims |
| Bristol Myers SquibbRevlimid | $94 | $232,67713 claims |
| PfizerEliquis | $310 | $49,92549 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Belpre
- Afshin DowlatiCleveland$25.1M
- Brian HillCleveland$11.6M
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- Christopher HoimesCleveland$7.5M
- Balazs HalmosCleveland$7M
- David WaterhouseCincinnati$5.7M
- Dale ShepardCleveland$5.1M
- Paolo CaimiCleveland$4.2M
- Allison WinterCleveland$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.